Novartis gains global rights to an Arvinas protein degrading drug that targets the androgen receptor to treat prostate cancer. The deal also includes a preclinical molecule addressing an androgen receptor variant.
A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Despite achieving its Phase 3 study's main goal, the results for Point Biopharma's therapy are short of what Novartis radiopharmaceutical Pluvicto achieved in a similarly designed clinical trial. Nevertheless, the data readout should clear the way for Eli Lilly to complete its $1.4 billion acquisition of Point.
Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.
Johnson & Johnson’s Akeega is approved for treating advanced prostate cancer with a BRCA mutation. The drug, which interferes with a way cancer cells repair themselves, will compete against recently approved drugs from Pfizer and partners AstraZeneca and Merck.
Appropriate Medicare reimbursement of high-intensity focused ultrasound for prostate disease is a significant development for the treatment for men 65 years and older today.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Avenda Health, a startup focused on personalized prostate cancer care, recently received 510(k) clearance from the FDA for its cancer mapping platform. The platform uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins.
Avenda Health, an AI company focused on personalized prostate cancer care, recently closed a $10 million Series B funding round. The company's platform seeks to personalize treatment to the patient and their specific case to preserve quality of life and prevent cancer recurrence.
Merck is partnering with Orion on the clinical development and potential commercialization of a new drug for advanced prostate cancer. Though Merck already has a piece of the prostate cancer drug market, Orion’s drug would offer a new approach for treating cancers that have become resistant to currently available hormone therapies.
Studies have shown that men are less likely to use preventive healthcare services than women, and do not seek immediate treatment for many of their unique health problems.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four years ago.
Harpoon Therapeutics is discontinuing work on its lead drug in prostate cancer following disappointing data in an early-stage clinical trial. Though Harpoon has other drugs in its pipeline, the decision is a setback to the company’s efforts to develop a new type of cancer immunotherapy.
Paige received clearance from the Food and Drug Administration for a clinical decision support tool to flag potential prostate cancer cases for pathologists to review.
Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.
Tel Aviv-based Ibex Medical Analytics published data on what it called the first algorithm to go beyond detection and into areas like tumor grading and sizing.